GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma AS (OTCPK:ZLDPF) » Definitions » Shares Outstanding (Basic Average)

ZLDPF (Zealand Pharma AS) Shares Outstanding (Basic Average) : 70.74 Mil (As of Dec. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Zealand Pharma AS Shares Outstanding (Basic Average)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Zealand Pharma AS's average basic shares outstanding for the quarter that ended in Dec. 2024 was 70.74 Mil.


Zealand Pharma AS Shares Outstanding (Basic Average) Historical Data

The historical data trend for Zealand Pharma AS's Shares Outstanding (Basic Average) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zealand Pharma AS Shares Outstanding (Basic Average) Chart

Zealand Pharma AS Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shares Outstanding (Basic Average)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 38.37 42.87 46.20 56.59 66.43

Zealand Pharma AS Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Shares Outstanding (Basic Average) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 58.37 61.63 62.69 70.66 70.74

Zealand Pharma AS Shares Outstanding (Basic Average) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Zealand Pharma AS  (OTCPK:ZLDPF) Shares Outstanding (Basic Average) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.


Be Aware

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Zealand Pharma AS Shares Outstanding (Basic Average) Related Terms

Thank you for viewing the detailed overview of Zealand Pharma AS's Shares Outstanding (Basic Average) provided by GuruFocus.com. Please click on the following links to see related term pages.


Zealand Pharma AS Business Description

Industry
Traded in Other Exchanges
Address
Sydmarken 11, Soborg, DNK, DK-2860
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.

Zealand Pharma AS Headlines

From GuruFocus

Zealand Pharma A/S Obesity R&D Event Transcript

By GuruFocus Research 02-15-2024

Q3 2024 Zealand Pharma A/S Earnings Call Transcript

By GuruFocus News 11-08-2024

Q1 2022 Zealand Pharma A/S Earnings Call Transcript

By GuruFocus Research 02-15-2024

Q2 2023 Zealand Pharma A/S Earnings Call Transcript

By GuruFocus Research 02-15-2024

Half Year 2024 Zealand Pharma A/S Earnings Call Transcript

By GuruFocus Research 08-16-2024

Q1 2024 Zealand Pharma A/S Earnings Call Transcript

By GuruFocus Research 05-17-2024

Q1 2023 Zealand Pharma A/S Earnings Call Transcript

By GuruFocus Research 02-15-2024

Zealand Pharma A/S Corporate Update Call Transcript

By GuruFocus Research 02-15-2024